Prospects for application of polyphenolic products of grape processing in maxillofacial surgery
Bezrukov SG, Ivashchenko NA, Tarimov KO, Bezrukov GS, Yelcheva LA
259 maxillofacial patients with metabolic syndrome (MS) as a concomitant disease were under observation. They underwent treatment in in-patient department and entered sanatorium-resort rehabilitation. Numbers of patients with coronary heart disease (CHD) amounted to 96 patients and patients with hypertension (HD) amounted to 163, these diagnosis CHD and HD was established earlier in medical institutions. Complex therapy for patients in the main groups additionally included polyphenols in the form of red grape processing products (Enoant for 1st main group and Fenokor for 2d main group) with calculation of 10 mg of total polyphenols per 1 kg of body weight. The control group included 40 people - patients with CHD, comparable in age and sex, who received only basic sanatorium resort treatment without polyphenols application. Patients underwent biochemical and immunological examination. The decrease in the intensity of the systemic inflammatory response was confirmed by both clinical data and a significant decrease in the level of leukocytes, especially in patients with CHD. So in the group with Enoant application, the level of leukocytes decreased by 24.2% (p < 0.01), in the group using Fenokor decreased by 29.4% (p< 0.01). The prescription of Fenokor reduced ESR by 37% (p 0.1), Enoant reduced by 28% (p> 0.1). In the study groups using grape processing products (UGPP), a decrease in the level of secondary products of lipid peroxidation (LPO) was evident on the fifth day by 30.3% (p < 0.001), while using Fenokor, which is 10.6% and 13.4%, respectively different from the data obtained in the control group. The use of UGPP also contributed to a decrease in the level of C-reactive protein (CRP) in patients with metabolic syndrome. Thus, in the group of patients with CHD, the administration of Fenocor and Enoant led to a decrease in the level of CRP in patients by 42.7% (p <0.002), and in the group of patients with hypertension - by 39.9% (p <0.001) in comparison with the initial indicators. At the same time, a decrease in CP of blood plasma by 12.4% was observed in both main groups (p = 0.064). This suggests that UGPP can be used in the complex treatment of maxillofacial patients, to optimize recovery processes, as well as to reduce the risk of complications caused by the influence of concomitant pathology (metabolic syndrome, HD and CHD).